Obesity is a global health crisis, with over 650 million adults affected worldwide. This drives massive economic and disease burdens. Yet new treatment options like GLP-1 drugs offer hope. This episode analyzes the investment landscape and future of obesity therapeutics, focusing on transformational GLP-1 drugs like Ozempic that curb appetite. Join us as we investigate the promise and challenges of emerging anti-obesity drugs, learn about one patient’s journey taking them, and discover what the future of weight loss medicine could look like. You'll hear from leaders in the space as well as a current patient taking these medications. Guests include:
Rod Wong, Founder, Managing Partner, and Chief Investment Officer at RTW Investments
Raymond Stevens, Ph.D., Chief Executive Officer at Structure Therapeutics
Dean Dimizas, Partner and Managing Director at Cambridge Associates
Kathleen Mikaelian, Patient
Unseen Upside: Investments Beyond Their Returns is developed in partnership with PRX, an award-winning podcast media company. Cambridge Associates is a global investment firm that works with endowments, foundations, healthcare systems, pension plans, and private clients to implement and manage custom investment portfolios that aim to generate outperformance and maximize their impact on the world. Cambridge Associates delivers a range of portfolio management services, including outsourced CIO, non-discretionary portfolio management, staff extension, and asset class mandates.
Podden och tillhörande omslagsbild på den här sidan tillhör Cambridge Associates. Innehållet i podden är skapat av Cambridge Associates och inte av, eller tillsammans med, Poddtoppen.
